Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies is a phase 3 interventional study registered as NCT07648264 by CSL Behring, with 63 participants planned, started 2026-09-11 and due to reach its primary completion in 2029-03-13. Interventions recorded: IgPro20.